SCHEMBL3929607

SCHEMBL3929607

O=C(O)[C@@H]1CCCN(C2CCNCC2)C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.55
TSHR P16473 2/20 0.50
GABRP O00591 1/20 0.50
GABRD O14764 1/20 0.50
GABRA1 P14867 1/20 0.50
GABRB1 P18505 1/20 0.50
GABRG2 P18507 1/20 0.50
GABRB3 P28472 1/20 0.50
GABRA5 P31644 1/20 0.50
GABRA3 P34903 1/20 0.50
GABRA2 P47869 1/20 0.50
GABRB2 P47870 1/20 0.50
GABRA4 P48169 1/20 0.50
GABRE P78334 1/20 0.50
PMP22 Q01453 1/20 0.50
GABRA6 Q16445 1/20 0.50
GABRG1 Q8N1C3 1/20 0.50
GABRG3 Q99928 1/20 0.50
GABRQ Q9UN88 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19815499 1.00 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2TSHRGABRPGABRD
Hydrochloric Acid SCHEMBL16823920 0.98 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2TSHRGABRPGABRD
SCHEMBL10859973 0.85 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2HTR2AHRH1HTR2C
SCHEMBL5912608 0.84 KMT2A (0.46) ALDH1A1SMN1; SMN2LMNAL3MBTL3L3MBTL1
SCHEMBL13609481 0.81 CHRNB2 (0.49) ALDH1A1SMN1; SMN2TSHRLMNAL3MBTL3
Hydrochloric Acid SCHEMBL29098543 0.81 TSHR (0.58) ALDH1A1SMN1; SMN2TSHRGABRPGABRD
Hydrochloric Acid SCHEMBL4297704 0.80 CHRNB2 (0.47) ALDH1A1SMN1; SMN2TSHRLMNAL3MBTL3
SCHEMBL13609482 0.80 HPGD (0.50) ALDH1A1SMN1; SMN2TSHRLMNAL3MBTL3
SCHEMBL4155085 0.79 TSHR (0.61) ALDH1A1SMN1; SMN2TSHRGABRPGABRD
Hydrochloric Acid SCHEMBL4302489 0.79 HPGD (0.49) ALDH1A1SMN1; SMN2TSHRLMNAL3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560569-B2 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity KYORIN PHARMACEUTICAL CO., LTD (JP) 2009-07-14 US disclosed
US-20070265320-A1 Bicycloamide Derivative KYORIN PHARMACEUTICAL CO., LTD (JP) 2007-11-15 US disclosed
EP-1717225-A1 BICYCLIC AMIDE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2006-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265320-A1 Bicycloamide Derivative DPP4, DPP7, DPP9 ALDH1A1 71/4885SMN1; SMN2 2259/4885TSHR 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.